Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary ...

Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...

EZO, a leading provider of intelligent asset management solutions, unveiled the next phase of its brand evolution, solidifying its commitment to providing operations teams with streamlined, ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

Recently published research led by Cincinnati Children's experts demonstrates both the need for, and effectiveness of, a program to train pediatric care providers to have conversations with patient ...

The event brought together 300 researchers, clinicians, industry leaders, and entrepreneurs to highlight their work.

Ataxia-telangiectasia (A-T) remains an incurable disease with limited treatment options. The progression of clinical trials is hindered by the lack of diagnostic and disease progression biomarkers for ...